EMPA-REG HF Event Reduction Index Calculator

Clinical calculation support · Verify results before clinical use

Estimate absolute risk reduction

Enter the estimated annual risk of heart failure hospitalization and a projection period.

35%RRR input
Use a percentage from 0 to 100. This input is for heart failure hospitalization alone, not cardiovascular death or a composite endpoint.
% / year
Enter a duration greater than 0 and up to 50 years. Longer projections are increasingly uncertain.
years
—percentage points
Illustrative absolute risk reduction

Enter values to calculate

The estimate will appear here. This is a simplified projection, not a validated individual treatment-benefit prediction.

MeasureProjected value
Risk without treatment over the selected period—
Risk with the assumed effect of empagliflozin—
Absolute risk reduction (ARR)—
Illustrative number needed to treat (NNT)—

About this estimate

The EMPA-REG OUTCOME trial studied empagliflozin in people with type 2 diabetes and established cardiovascular disease. In the trial, hospitalization for heart failure occurred in 2.7% of participants receiving empagliflozin and 4.1% receiving placebo; the hazard ratio was 0.65 (95% CI 0.50–0.85).

This tool applies a simplified 35% relative reduction assumption to a user-entered annual heart failure hospitalization risk. It compounds the annual risk over the selected period, assuming the same baseline risk and treatment effect each year. That assumption is mathematical and has not been validated as an individualized prediction model.

How to interpret the result

  • The ARR is the modeled difference between projected risks, expressed in percentage points.
  • The NNT is the reciprocal of the modeled ARR over the selected period, rounded up; it is illustrative and should not be interpreted as a trial-derived NNT.
  • Absolute benefit depends on baseline risk and the time horizon. Uncertainty increases when extrapolating beyond the trial follow-up or population.

Important scope limitation

The 35% estimate refers to hospitalization for heart failure in EMPA-REG OUTCOME. It should not be applied to cardiovascular death or interpreted as a validated effect for a combined endpoint. The trial population and background care may differ from an individual patient or other clinical populations.

References

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373:2117–2128. DOI: 10.1056/NEJMoa1504720.
Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial. European Heart Journal. 2018;39(5):363–370. DOI: 10.1093/eurheartj/ehx511.
Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. European Heart Journal. 2016;37(19):1526–1534. DOI: 10.1093/eurheartj/ehv728.